![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES BARR'S GENERIC ALLEGRA
FDA APPROVES BARR'S GENERIC ALLEGRA
July 20, 2005
Barr Laboratories has received final approval from the FDA to market its generic version of Aventis Pharmaceuticals' Allegra (fexofenadine HCl) capsules in a 60-mg dosage strength. Barr was the first generic company to file an abbreviated new drug application (ANDA) with a Paragraph IV challenge on the Allegra allergy-treatment capsule, which entitles the firm to 180 days of marketing exclusivity for the 60-mg generic product, the company said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct